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Abstract
Pyruvate kinase M2 (PKM2) is an alternatively spliced variant, which mediates the conver-
sion of glucose to lactate in cancer cells under normoxic conditions, known as the Warburg
effect. Previously, we demonstrated that PKM2 is one of 97 genes that are overexpressed
in non-small-cell lung cancer (NSCLC) cell lines. Herein, we demonstrate a novel role of
subcellular PKM2 expression as a biomarker of therapeutic response after targeting this
gene by shRNA or small molecule inhibitor (SMI) of PKM2 enzyme activity in vitro and in
vivo. We examined two established lung cancer cell lines, nine patients derived NSCLC and
three normal lung fibroblast cell lines for PKM2 mRNA, protein and enzyme activity by RT-
qPCR, immunocytochemistry (ICC), and Western blot analysis. All eleven NSCLC cell lines
showed upregulated PKM2 enzymatic activity and protein expression mainly in their cyto-
plasm. Targeting PKM2 by shRNA or SMI, NSCLC cells showed significantly reduced
mRNA, enzyme activity, cell viability, and colony formation, which also downregulated cyto-
solic PKM2 and upregulated nuclear enzyme activities. Normal lung fibroblast cell lines did
not express PKM2, which served as negative controls. PKM2 targeting by SMI slowed
tumor growth while gene-silencing significantly reduced growth of human NSCLC xeno-
grafts. Tumor sections from responding mice showed >70% reduction in cytoplasmic PKM2
with low or undetectable nuclear staining by immunohistochemistry (IHC). In sharp contrast,
non-responding tumors showed a >38% increase in PKM2 nuclear staining with low or
undetectable cytoplasmic staining. In conclusion, these results confirmed PKM2 as a target
for cancer therapy and an unique function of subcellular PKM2, which may characterize
therapeutic response to anti-PKM2 therapy in NSCLC.
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Introduction
Lung cancer is the most common cause of cancer related mortality worldwide, accounting for
approximately 1 in 4 cancer deaths [1, 2]. About 85–90% of lung cancers are non-small-cell-
lung cancer [3, 4]. For early stage Non-Small-Cell Lung Cancer (NSCLC), surgery is usually
the treatment of choice and chemotherapy (sometimes in combination with radiation therapy)
may be given as well. Patients with advanced-stage NSCLC are usually treated with chemother-
apy, targeted drugs (or a combination of the two), or immunotherapy. Considering the low
5-year survival rate (21%) with currently available therapies, there is a need for improved treat-
ment options [4]. Compared to normal cells, cancer cells display a radical shift in metabolism
becoming highly dependent on glucose, which is metabolized through an increased rate of aer-
obic glycolysis, a metabolic state termed the Warburg effect, which is considered a hallmark of
cancer metabolism [5, 6]. Previously, we have demonstrated that human NSCLC cell lines
overexpress 97 genes by DNA microarray [7–9]. Among these, pyruvate kinase M2 (PKM2) is
highly overexpressed in NSCLC cell lines examined compared to normal lung tissues. PKM2 is
an allosteric isoform of pyruvate kinase, which catalyzes the final step in glycolysis and con-
verts phosphoenol-pyruvate (PEP) to pyruvate [10]. PKM2 is shown to divert glycolytic flux
into the pentose phosphate pathway associated with attenuated pyruvate kinase activity,
thereby meeting the biosynthetic demands for rapid proliferation [10]. Of four isoforms of
pyruvate kinase L, R, M1 and M2, proliferating embryonic and tumor cells predominantly
express PKM2. In cancer cells, PKM2 can migrate to the nucleus and function as a transcrip-
tional co-factor in response to many extracellular signals such as Epidermal growth factor
(EGF) and hypoxia, which activate CYCLIN D1, C-MYC or Hypoxia inducible factor-alpha
(HIF-α) [11, 12]. PKM2 is shown to mediate epithelial to mesenchymal transition (EMT),
which stimulates PKM2 to migrate to nucleus in cancer cells and acts as a transcription cofac-
tor that in turn inhibits E-cadherin [13]. It is also shown that cytosolic PKM2 is associated
with Epidermal growth factor receptor (EGFR) expression and prolongs the protein half-life of
EGFR in cancer cells by stabilizing EGFR-Heat shock protein 90 (HSP90) protein complex
[14]. PKM2 is reported to act as a protein kinase and exist as a dimer localized in the nucleus
promoting cell proliferation, while its tetramer form is an active pyruvate kinase localized in
the cytosol [15]. It is also reported that nuclear translocation of PKM2 supports cancer cell sur-
vival, which binds to Oct4 promoting expression of cancer stemness-related genes [16].
Targeting colorectal cancer cell lines with gefitinib (a tyrosine kinase inhibitor) or oxalipla-
tin revealed that nuclear PKM2 contributed to therapeutic resistance in vitro and in vivo mod-
els of colorectal cancer [17, 18]. Further, it is reported that selective inhibition of PKM2
isoform with small molecules and RNAi reduced cell proliferation in human lung cancer cells
in vitro [19]. As many oncogenes can influence glucose metabolism in cancer cells, inhibition
of the PKM2 isoform may have a variable degree of therapeutic applicability for in vitro and in
vivo models of human cancers. Silencing PKM2 specific RNA decreased cell viability and
increased apoptosis in several cancer cell lines in vitro and regressed tumor volumes by deliver-
ing them in in vivo mouse models of hepatocellular and ovarian cancer [20]. Additionally,
PKM2 also acts as a protein kinase in the nucleus upon EGFR activation, hypoxia or glucose
depletion, where it can enhance the proliferation and survival of certain types of cancer cells in
response to mitogen activation or hypoxic stress [19, 21–23]. Previous studies have shown that
PKM2 can act as one of the downstream transcriptional coactivators of EGF/EGFR signal
transduction, which promotes disease progression in glioma cells and it might be upregulated
through the EGFR-dependent NF-kB activation [23, 24]. As PKM2 inhibits P53-dependent
transactivation of the P21 gene by preventing P53 binding to the P21 promoter, it may lead to
increased G1 phase activity, thus providing a growth advantage for tumor cells in the presence
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Abbreviations: FBP, fructose-1,6-bisphosphate;
NSCLC, non-small-cell lung cancer; PEP,
phosphoenol-pyruvate; PKM2, pyruvate kinase M2.
of a DNA damage stimulus [25]. PKM2 isoform is expressed universally in many types of rap-
idly growing cells such as embryonic cells and cancer cells, which supports cancer growth by
regulating a group of genes involved in cell proliferation, migration and apoptosis [26].
Because patient-derived and established NSCLC cell lines showed overexpression of PKM2
and PKM2 enzyme activities, we hypothesized that inhibiting enzyme activity by small mole-
cule inhibitor (SMI) or gene silencing by shRNA (shRNA-PKM2) might influence NSCLC
growth kinetics. Here, we tested whether SMI and shRNA-PKM2 influence NSCLC growth
kinetics in vitro and in vivo. Our results demonstrate that PKM2 is primarily expressed in the
cytosol of NSCLC cells and xenograft tumor cells. Both approaches (SMI and shRNA-PKM2)
not only inhibited the PKM2 enzyme activity and cell proliferation in NSCL cells, but also
decreased PKM2 mRNA expression and ultimately led to cell killing by apoptosis. Addition-
ally, our results showed a unique subcellular compartmentalization of PKM2 in NSCLC cells
and xenografts upon treating them with anti-PKM2 therapies in vitro and in vivo indicating
that PKM2 expression may serve as a biomarker of therapeutic response in NSCLC.
Materials and methods
Cell lines and treatment
We studied nine patient-derived NSCLC cell lines, which were previously established at the Earle
A. Chiles Research Institute, Portland, OR. The two cell lines established at the NCI (H1299 and
H358) and 3 normal lung fibroblast cell lines (WI-38, HEL-299 and IMR-90) were purchased
from ATCC and were maintained in the ATCC recommended complete medium. These cells
lines were purchased from ATCC within first two years of undertaking experiments and if not
their identity was confirmed by short-tandem repeats (STR) profiling. The nine cell lines from
the Earle A. Chiles Research Institute were cultured in complete medium with 10% FBS. A small
molecule inhibitor (SMI) of the PKM2 enzyme inhibitor (SMI-Compound 2825–0090, N-(3-car-
boxy-4-hydroxy) phenyl 1–2,5,-dimethylpyrole) was purchased from ChemDiv (San Diego, CA)
and dissolved in PBS for treating the NSCLC and normal lung cell lines. For PKM2 targeting in
NSCLC cell lines, shRNA (AGAGCCTACCTGTATGTCAAT) and control plasmids (AGAGCCT
ACCTGTATGTCAAT) were purchased from Qiagen (Qiagen, Germantown, MD) and trans-
fected by using Attractene transfection reagent (Qiagen) as suggested by the manufacturer.
RT-qPCR
Total RNA from 3 normal lung and 11 NSCLC cell lines was extracted after incubating them
with different concentrations of PKM2 inhibitor (1 to 80 μM) for 48 hours at 37˚C in a CO2
incubator using RNA-easy mini prep kit (Qiagen) following the manufacturer’s instructions
and amplified using forward; CTATCCTCTGGAGGCTGTGC and backward; CCAGACTTGGT
GAGGACGAT primers for human PKM2. β-actin gene specific primers (forward: TGAGAGG
GAAATCGTGCGTG and backword TGC TTG CTG ATC CAT ACC ATC TGC) were used to
amplify β-actin as a house keeping gene for quantitative expression of PKM2 mRNA [27, 28].
Briefly, 100ng of total RNA was reverse transcribed by using one step RT-qPCR kit using CFX
96 Real time detection system (Bio-Rad, Hercules, CA) using gene specific primers (Bio-Rad,
Hercules, CA) as recommended by the manufacturer. Each sample was run in triplicate and
the data were expressed as % ratio of relative fluorescence units of PKM2and β -actin.
Pyruvate kinase activity
Pyruvate kinase activity in control, SMI-treated or shRNA-transfected NSCLC cells was mea-
sured by a continuous assay coupled to lactate dehydrogenase (LDH). To assess activity in cell
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lysates, cells were treated with SMI for the indicated time and lysed in NP40 containing 25 μM
Tris/Cl pH 7.4 lysis buffer immediately before measuring pyruvate kinase activity as described
previously [10, 29]. Briefly, the change in absorbance at 340 nm, caused by oxidation of
NADH, was measured using Ultrospec 2000 spectrophotometer (Pharmacia/LKB,). The assay
was performed in triplicate from each sample lysate and values were expressed as % normal
lung cell line lysates.
Cell viability assay
Cell viability of NSCLC cell lines was measured by trypan blue exclusion technique. The num-
ber of viable cells was manually counted using a hemocytometer and expressed as % of
untreated cells [30, 31].
Clonogenic assay
Colony formation of NSCLC cell lines in SMI-treated or shRNA targeted cultures was mea-
sured in vitro as described previously [32]. The number of colonies formed were counted and
expressed as number of colonies in untreated, SMI treated or shRNA-PKM2 transfected cell
cultures.
Assessment of apoptosis
Patient-derived and established NSCLC cell lines were seeded in 4 well glass chambered slides
and incubated with 0–80 μM of SMI for 5 days. After a brief wash with 1x PBS, the TUNEL
positive apoptotic cells were counted as per manufacturer’s instructions (Promega Corpora-
tion, Madison, WI). The assay was performed in triplicate and data were shown as mean ± SD.
Intracellular caspase3/7 activity was measured from control (untreated), sh-negative control
and shRNA-PKM2 transfected NSCLC cells using earlytox Caspase-3/7 R100 assay kit follow-
ing manufacturer’s recommendations (Molecular Device, Sunnyvale, CA). The endpoint fluo-
rescence was measured on a SpectraMax M5 plate reader and each value is expressed as
arbitrary fluorescence units.
Immunocytochemical and immunohistochemical analysis (ICC and IHC)
PKM2 expression in NSCLC cells and xenografts sections was analyzed by ICC and IHC tech-
niques as described previously [28, 33]. For PKM2 expression in NSCLC xenografts, the cryo-
sections were immunostained with rabbit monoclonal anti-PKM2 antibody (clone EPR10138,
Abcam, Cambridge, MA) and DAPI also as described above. The degrees of cytoplasmic and
nuclear PKM2 fluorescence in red and nuclear staining with DAPI in blue fluorescence in sec-
tions were evaluated for subcellular compartmentalization of PKM2 expression by using
Nikon-S- Element software (Nikon, Melville, NY). The extent of immunostaining was evalu-
ated as�1+, negative; 2+, positive; 3+, strongly positive; 4+, more strongly positive. Three
independent investigators (BJ, AS, SP) scored IHC images in a blinded fashion for subcellular
localization of PKM2 levels.
Subcellular fractionation
Twenty million NSCLC or normal lung cells were washed with 1x PBS before processing for
subcellular fractionation. Nuclear and cytoplasmic fractions from NSCLC cells and xenografts
were prepared using NE-PER nuclear and cytoplasmic extraction reagents (Pierce Biotechnol-
ogies, Rockford, IL, now Thermofisher Scientific, Waltham, MA). All cytoplasmic and nuclear
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fractions were stored at -80˚C until analyzed for PKM2 or Caspase activity or Western blot
analysis.
Western blot analysis
500,000 NSCLC cells were seeded in a 10-cm tissue culture plate and treated with different
concentrations of SMI when the cell confluency was between 50–60%. After 48 hours, total cell
lysate, subcellular fractions (cytosol/nuclear fractions) were prepared using NE-PER reagents
as described above. The supernatant from total cell lysate, nuclear and cytosol fractions were
quantitated by Bio-Rad protein assay (Bio-Rad, Hercules, California). Twenty micrograms of
protein equivalent lysates were boiled in 4 x SDS sample loading buffer and run on mini-Pro-
tean TGX AnyKd gel (Bio-Rad). The proteins were transferred to nitrocellulose and Western
blots were performed using rabbit monoclonal anti-PKM2 antibody (AbCam, Cambridge,
MA) and incubated with IR Dye 800CW near-infrared fluorescent goat anti-rabbit IgG sec-
ondary antibody (LI-COR, Lincoln, NE). The membrane was washed three times and scanned
using Odyssey CLx system (LI-COR, Lincoln, NE).
In vivo PKM2 targeting study
Female nude nu/nu mice aged between 6 and 7 weeks were housed in a temperature-con-
trolled, pathogen-free animal facility with 12-hour light and dark cycles. All animal studies
were conducted under approved protocol #1992–42 by the CBER Institutional Animal Care
and Use Committee (ACUC) in accordance with the principles and procedures outlined in the
NIH Guideline for the Care and Use of Laboratory Animals. All animal experiments were per-
formed under ABSL-2 conditions in a facility accredited by the Association for Assessment
and Accreditation of Laboratory Animal Care (AAALAC). Animals were monitored daily
with increased monitoring at a minimum of twice daily during experiments. The analgesics
were not used to avoid their possible interference in PKM2 signaling and translocation to
tumor cell organelles and in tumor microenvironment. Euthanasia before tissue harvest was
by ketamine/xylazine overdose while euthanasia due to body weight loss or termination of
study was by carbon dioxide inhalation in a chamber where the carbon dioxide was from a cyl-
inder source delivered by Euthanex equipment (Palmer, PA).
Five million H358 cells were injected subcutaneously into the right flank of each mouse.
When tumors reached 5 mm in diameter, H358-tumor-bearing mice were injected with differ-
ent doses of PKM2 inhibitor (0, 50, or 500 μg/kg/day) once a day on alternate days for 12 days
(total 6 injections) by i.t. injection. Tumor size was measured weekly and overall sacrifice time
(OST) of the animals was calculated based on the sacrifice of mice when tumors reached 2 cm
in diameter, according to NIH animal guidelines. Mice were weighed at day 10 and day 25
after PKM2 inhibitor treatment. Experiments were repeated twice.
Similarly, 5x106 shRNA-PKM2 gene silenced or negative control plasmid transfected H358
cells were implanted in six-week-old female nu/nu mice, weighing 17-20g for developing xeno-
grafts as described above. Before implanting the cells, they were either PKM2 gene silenced,
mock-transfected or negative control plasmid transfected and selected by using G148 antibiotic.
The transfected NSCLC cells were tested for PKM2 RNA and protein by RT-qPCR and IFA
assays. For these experimental differences of transfection and selection involved in before
implanting the cells in mice, the control group of mice was different compared to SMI treated
mice, which were labeled as non-silenced mice in which negative control sh-RNA plasmid was
used. The therapeutic response and OST were evaluated between these two groups. The xeno-
grafts in mice, which responded to anti-PKM2 therapy (either SMI or shRNA-PKM2) were
referred to regressing tumors and those not responding were termed as non-regressing tumors.
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Statistical analysis
Statistical analysis was performed using Student’s t test for comparison between two groups or
ANOVA among more than two groups of mice using Graph Pad Prism program (GraphPad
Software, La Jolla, CA). Survival curves were generated by the Kaplan-Meier method and com-
pared by using the log-rank test. The level of statistical significance was set at a P value of
�0.05.
Results
PKM2 is overexpressed in NSCLC cell lines
We observed that all patient-derived and established NSCLC cell lines significantly overexpress
PKM2 mRNA ranging from 5.3 to 16.5 times greater than normal lung cell lines (P�0.0001,
Fig 1A). Further, PKM2 enzyme activity was markedly higher in all 11 NSCLC cell lysates
compared to three normal lung cell lines (P�0.0001, Fig 1B), corroborating RT-qPCR results
of mRNA overexpression. We confirmed these data by analyzing all NSCLC cell lines for
PKM2 protein expression by ICC using rabbit monoclonal antibody. ICC results for all these
cell lines showed�2+ immunostaining intensity in all 11 NSCLC cell lines with 55–86% posi-
tively stained cells. In contrast, the extent of immunostaining in three normal lung cell lines
was� 1+ and 8–12% cells were positive for immunostaining (S1 Table and S1 Fig).
PKM2 supports tumor growth of NSCLC cell lines
Based on RT-qPCR, PKM2 enzyme activities and ICC results, we hypothesized that PKM2
may have a critical role in NSCLC cell growth. As shown in Fig 2A, all NSCLC cell lines dem-
onstrated a significant and concentration-dependent decrease in PKM2 mRNA expression
after treating either with SMI for 48 hours (P = 0.0023) or PKM2 gene silencing (P = 0.001)
compared to untreated (none) or negative control shRNA transfected cells. But normal lung
fibroblast cell lines did not show such dramatic response to SMI treatment (Fig 2A). Further,
SMI treatment and shRNA-PKM2 resulted in a significant decrease in PKM2 enzyme activity
(P<0.005 and P<0.00012) and a marginal decrease in normal lung cell lines (Fig 2B) com-
pared to corresponding untreated control cell lines. As shown in Fig 2C, we confirmed RT-
qPCR and PKM2 enzyme data by performing Western blot analysis from total cell lysates of
untreated (labeled as none), treated with different concentrations of SMI and shRNA-PKM2
cell lysates. We observed that no treatment (none) and shRNA negative control lysates showed
similar values, and therefore pooled together in Fig 2A, 2B and 2C. Interestingly, PKM2 pro-
tein levels by Western blot corroborated the RT-qPCR and PKM2 enzyme activity (Fig 2D),
which demonstrated a concentration dependent decrease in PKM2 protein levels, although
none of these two approaches completely blocked PKM2 expression even at higher than
65 μM concentrations of SMI (data not shown).
Further, targeting PKM2 with SMI resulted in a concentration-dependent decrease in
NSCLC cell viability where the IC50 of SMI (concentration of SMI causing 50% inhibition of
NSCLC cell line growth) ranged between 30–65 μM (Fig 3A). At 20 μM SMI concentration,
~80% cells were viable. Normal fibroblast lung cell lines did not demonstrate sensitivity to
SMI, which corroborated RT-qPCR and ICC data showing low expression of PKM2 (S2
Table). These observations were independently confirmed by testing the effect of SMI/
shRNA-PKM2 on colony formation of NSCLC in vitro (Fig 3B and 3C). The number of colo-
nies from NSCLC cells treated with SMI decreased significantly (P<0.001). Under similar SMI
treatment conditions, we observed approximately 50% decrease in number of colonies at
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Fig 1. PKM2 expression in normal lung and NSCLC cell lines. (A) mRNA levels and (B) PKM2 enzyme activity were measured in 3 normal lung and 11 NSCLC cell
lines. Each value is expressed as mean % of normal lung cell lines.
https://doi.org/10.1371/journal.pone.0217131.g001
Fig 2. Effect of SMI on mRNA expression, enzyme activity and protein expression by Western blot analysis. Three normal
lung and 11 NSCLC cell lines were treated with different concentrations of PKM2 inhibitor (10 to 80 μM). (A) Total RNA from
the cells was extracted and real-time PCR was performed. Relative expression of mRNA for PKM2 and β-actin is shown as mean %
of untreated normal lung cell line (Relative Fluorescence Units-RFU). (B) PKM2 enzyme activity was measured. Each value is
expressed as mean % of untreated normal lung cell lines. (C) Expression of PKM2 in one representative NSCLC cell line treated
with different concentration of SMI and shRNA-PKM2 was determined by Western blot analysis. (D) Semi-quantitation of
immunoblot was performed using image studio software. Dotted line indicated 50% arbitrary units of band intensity.
https://doi.org/10.1371/journal.pone.0217131.g002
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�65 μM SMI, which corroborated its effects on cell viability in a concentration-dependent
manner in SMI treated NSCLC cultures.
To examine whether PKM2 is critical for cell viability of NSCLC cells, we analyzed cell via-
bility in shRNA-PKM2 transfected cell lines by trypan blue dye exclusion technique. sh-
RNA-PKM2 also caused a marked reduction in cell viability and colony formation (P<0.001;
Fig 3A–3C). Indirect immunofluorescence analyses of SMI treated or shRNA-PKM2 NSCLC
cell lines revealed a significant decline in the extent of immuno-staining and the percentage of
PKM2 positive cells compared to corresponding controls (S2 Table, P<0.0001).
Targeting of PKM2 by SMI or shRNA-PKM2 modulates subcellular PKM2
activity in vitro
As PKM2 is important for NSCLC cell growth in vitro, we further evaluated the functional
importance of subcellular PKM2 expression in terms of its subcellular localization and activity
in SMI treated or shRNA-PKM2 gene silenced NSCLC cell lines. We observed that the cyto-
plasmic PKM2 enzyme activity was significantly higher than nuclear enzyme activities
Fig 3. Effect of SMI on cell viability and clonogenicity of NSCLC cell lines. NSCLC cell lines were treated with different concentrations of SMI (10 to 80 μM). (A)
number of viable cells were expressed as % untreated cells counted by trypan blue exclusion technique in SMI treated and shRNA-PKM2 silenced 3 normal lung and 11
NSCLC cell lines. (B) For clonogenic assay, cells were incubated for 8 days to form colonies. Number of colonies was counted. (C) Number of colonies formed by
NSCLC cells treated with different concentrations of SMI and shRNA PKM2 were stained with 0.25% crystal violet in 25% ethanol, washed with water and air dried.
https://doi.org/10.1371/journal.pone.0217131.g003
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(P<0.001) in untreated NSCLC cell cultures. In contrast, treatment of NSCLC lines with SMI
for 48 hours or sh-RNA-PKM2 resulted in a decrease in cytoplasmic enzyme activity with a
concomitant rise in nuclear PKM2 enzyme activity (Fig 4A). Further, we observed that
untreated cells stained with rabbit monoclonal anti-PKM2 antibody showed spindle-shaped
morphology with red cytoplasm and hollow nucleus, while treated cells showed various pat-
terns of red signals; low signal in both cytoplasm and nucleus, small and round cells with
intense signal in both cytoplasm and nucleus, and spindle-shaped cells with red cytoplasm and
hollow nucleus (Fig 4B). As shown in (Fig 4A), treatment of NSCLC cell line with IC50 concen-
tration of SMI for 48 hours resulted in a decrease in cytoplasmic enzyme activity. By IFA anal-
ysis, we observed that for untreated NSCLC cells, anti-PKM2 antibody immunostaining
identified�2+ staining of cytoplasmic PKM2 and� 1+ staining of nuclei (Fig 4B). However,
SMI treatment showed a significant decrease in immunostaining for PKM2 in the cytoplasm
(� 1+) with a concomitant increase of immunostaining in nuclei (�2+) of established NSCLC
cell lines (Fig 4B and S3 Table). Consistent with these observations, NSCLC cell lines silenced
by the shRNA-PKM2 revealed a similar decrease in cytoplasmic PKM2 and increased expres-
sion in nuclei of NSCLC cells (S3 Table). Next, we performed Western blot analysis for PKM2
protein levels in cytoplasmic and nuclear fractions of SMI treated or shRNA-PKM2 NSCLC
cell lines. Fig 4C demonstrates a 58kDa PKM2 protein band in the immunoblot in which the
cytoplasmic PKM2 protein was decreasing in a concentration dependent manner upon treat-
ment with SMI or shRNA-PKM2 NSCLC cell lines. In contrast, the nuclear PKM2 protein was
increasing in NSCLC cell lines treated with SMI or gene silencing.
Targeting of PKM2 by SMI or shRNA-PKM2 induced apoptosis
To determine whether the effects of SMI or gene silencing on cell viability of NSCLC cell lines
are dependent on induction of apoptosis, we determined if the loss of viability is mediated by
Caspase 3/7 and induction of apoptosis in PKM2 depleted NSCLC and normal lung cell lines
by Tunel assay. We observed a concentration-dependent increase in apoptotic cells in SMI-
treated NSCLC cultures detected by the Tunel assay (Fig 5A). shRNA-PKM2 NSCLC cell lines
also showed a sharp increase in apoptotic cells compared to their negative control counterpart
cultures. As shown in Fig 5B, TUNEL assay microscopic images of SMI treated or
shRNA-PKM2 NSCLC cultures demonstrated increased number of apoptotic nuclei. We also
observed a significant increase in Caspase 3/7 activities (P = 0.0023) in SMI treated or
shRNA-PKM2 NSCLC cells compared to respective controls. In contrast, three normal lung
fibroblast cell lines failed to show such increase in Caspase 3/7 activities (Fig 5C).
Targeting of PKM2 by SMI or shRNA-PKM2 inhibited tumor growth of
NSCLC xenografts in vivo
To investigate whether PKM2 inhibition by SMI or shRNA-PKM2 mediated anti-tumor effects
in vivo, we first established xenografts using a slow growing H358 tumor cell line in athymic
nude mice by implanting 5 x 106 cells. When tumors reached to 62.5mm3, we treated mice
with 50 or 500 μg/kg doses of SMI intratumorally every alternate day for a total of 6 injections.
The control mice received PBS. We observed that the lowest dose SMI treatment did not
inhibit tumor growth (Fig 6A). However, the higher dose of SMI inhibited tumor growth.
Interestingly, the treatment of tumor bearing mice by 50 and 500 μg/kg SMI prolonged the
survival by a median of>80 days compared to control mice, however, no significant difference
was shown by log-rank test (Fig 6B). In contrast, shRNA-PKM2 xenografts showed a signifi-
cant reduction in tumor size over a follow up of 100 days compared to non-silenced and
mock-transfected xenografts (Fig 6C, P = 0.0146 and 0.0112, respectively). A significant
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increase in OST in mice with PKM2 silenced xenografts was observed compared to non-
silenced group (Fig 6D, P = 0.0178). However, OST between PKM2 silenced and mock-trans-
fected control xenografts was not significant (P = 0.0554). We also studied the effects of SMI
and shRNA-PKM2 on another fast-growing xenografts tumor model implanted with H1299
NSCLC cells and observed similar results. In brief, SMI showed modest effects on tumor
growth, however, shRNA-PKM2 xenografted animals showed a significant reduction in tumor
size (data not shown).
Toxicity of PKM2 inhibitor in murine models of NSCLC
We carefully monitored the general condition and body weight of mice to evaluate the general
toxicity of SMI and shRNA-PKM2 during the course of the experiment. We observed that
there was no significant difference in general appearance and body weight among four groups
of animals in both tumor models (data not shown).
Targeting of PKM2 modulates subcellular compartmentalization and
identifies therapeutic response
To determine whether PKM2 inhibition modulates subcellular compartmentalization, we eval-
uated cytoplasmic and nuclear staining by performing the experiments on two different
Fig 4. Effect of PKM2 inhibitor on subcellular localization of PKM2 enzymatic activities and protein levels. (A) Three normal lung and 11 NSCLC cell lines were
incubated with 65 μM of PKM2 inhibitor for 48 hours. Cytoplasmic and nuclear fractions were separated for PKM2 enzyme activity determination. Each value is
expressed as mean % cytoplasmic activity in untreated normal lung cell lines. (B) 25,000 H358 cells were plated in a multiwell-glass chamber and incubated for 48
hours with or without 65 μM of PKM2 inhibitor. Then, IFA was performed. PKM2 was stained with Alexa 594 (red). Untreated cells stained with anti-PKM2 antibody
showed spindle-shaped morphology with red cytoplasm and hollow nucleus while treated cells showed various patterns of red signals; low signal in both cytoplasm and
nucleus (arrow head), small cells with intense signal in both cytoplasm and nucleus (small arrow), and spindle-shaped cells with red cytoplasm and hollow nucleus (big
arrow). (C) Western blot analysis for PKM2 was performed from cytoplasmic and nuclear fractions of a NSCLC cell line treated with 10–80 μM of SMI or
shRNA-PKM2.
https://doi.org/10.1371/journal.pone.0217131.g004
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occasions resulting in four different readings to evaluate the extent of intensity for PKM2
immunostaining by viewing the specimens at 200 x magnification to score percent positive
fields in a blinded fashion for statistical significance. PKM2 intensity scores of� 2+ were con-
sidered positive, while� 1+ were considered negative. We observed a very high concordance
(exact 95% CI = 72.8–91.3) among the four sets of readings in both data sets (83.3%) obtained
from each independent experiment, where scores 3+ and 4+ were combined as 3+, while
scores 1+ and no score (value ±) were considered as 1+. These results demonstrate high preci-
sion in the IHC measurement for cytoplasmic and nuclear staining. For the remainder of the
analysis, discordant scores were resolved by assigning the majority score and when there was
an equal number of discordant scores, the lower score was used. For the rest of the analysis, all
discordant cases in PKM2 were coded as negative.
Fig 5. SMI and PKM2 silencing induced apoptosis in NSCLC cell lines. (A) Number of apoptotic nuclei by TUNEL assay were counted in 3 normal lung and 11
NSCLC cell lines after treating with 10–80μM of SMI or shRNA. Data are presented as mean ± SD from three independent experiments as described in Materials and
Methods. (B) 1000 x magnification image of a NSCLC cell line to show apoptotic nuclei after treating with 10–80μM of SMI in TUNEL assay (C) SMI treatment
induces Caspase 3/7 activity in normal lung and NSCLC cell lines in a concentration dependent manner. Data are presented as mean ± SD from three independent
experiments as described in Materials and Methods.
https://doi.org/10.1371/journal.pone.0217131.g005
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Nuclear PKM2 was identified as a merged immunostaining of PKM2 (red) with DAPI
(blue) staining as described in materials and methods. As shown in Fig 7A, tumors responding
to shRNA-PKM2 therapy demonstrated a significant decrease in cytosolic PKM2 in
shRNA-PKM2 treated mice xenografts (regressing) compared to parental or non-responding
tumor xenografts (non-regressing) (P�0.01). Immunostaining for nuclear PKM2 levels was
�1+ with ~10% of the positive fields in most of the regressing tumors (Fig 7B). In contrast, the
extent of IHC immunostaining in non-regressing xenografts showed a significant increase (3
+) in nuclear PKM2 and reduced levels of cytosolic PKM2 compared to regressing or corre-
sponding control (non-silenced) xenografts (P�0.01). Interestingly, cytoplasmic PKM2
Fig 6. Antitumor effect of PKM2 inhibitor and shRNA-PKM2 in NSCLC s.c. tumor models. (A) H358 tumors implanted mice were intratumorally treated with
PKM2 inhibitor when tumors reached 5 mm in diameter. Tumor volume of each mouse was measured. Bars represent S.D. Each arrow indicated SMI injection to
mice. On day 51, there was no significant difference between the groups. (B) Kaplan-Meier survival curves of H358 s.c. tumor-bearing mice after treatment were
plotted. Overall sacrifice time (OST) was calculated based on the sacrifice of mice when tumors reached>2cm. Median survival: Control 64 days, 50μg/kg 142 days,
and 500 μg/kg undefined. (C) H358 cells (non-silenced, mock-transfected, and PKM2-silenced) were implanted subcutaneously in nude mice and tumor volume was
measured. Bars represent S.D. On day 100, there was significant difference between the groups; parental vs PKM2-silenced and mock-transfected vs PKM2-silenced
(p = 0.0146 and 0.0112, respectively). (D) Kaplan-Meier survival curves of H358 s.c. tumor-bearing mice were plotted. Median survival: Non-silenced 102.5 days,
mock-transfected 113.5 days, PKM2-silenced undefined.
https://doi.org/10.1371/journal.pone.0217131.g006
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immunostaining intensity in non-regressing xenografts was lower (� 1+) in ~5% of the speci-
mens and higher in nucleus (3+) in� 75% than those seen in regressing tumor xenografts
(P�0.05; Fig 7B). But, >90% specimens from non-silenced control group showed 3+ cytosolic
PKM2 expression. In the mice with a therapeutic response to SMI or shRNA-PKM2 therapy, a
sum of the positive values of PKM2 (2+ and 3+ combined) showed a statistically significant
trend (non-silenced = 7% nuclear with 1+ and 88% cytoplasmic with 3+, non-regressing
tumors = 75% nuclear with 3+ and 9% cytoplasmic with 1+, regressing tumors = 17.7% nuclear
staining with 1+ and 12.56% cytoplasmic with 3+ PKM2 staining; exact P� 0.00012) com-
pared to negative values of PKM2 (� 1+) (Fig 7B).
Discussion
We have demonstrated overexpression of PKM2 in patient-derived and established NSCLC
cell lines. These cell lines not only overexpressed PKM2 protein but also high PKM2 enzyme
activity in>55% of the cells with> 2+ immunostaining intensity. The overexpressed PKM2
in NSCLC is inhibitable in a concentration-dependent manner with either a drug or gene
silencing by shRNA in vitro. These treatments affected both PKM2 enzyme activity and
mRNA transcription, which subsequently led to reduced levels of PKM2 protein, as demon-
strated by Western blot analysis. In contrast, three normal lung cell lines, which showed lower
enzyme activity and mRNA, did not show such a dramatic response to both types of anti-
PKM2 strategies. Further, we observed that PKM2 targeting with SMI or shRNA-PKM2
Fig 7. PKM2 expression in NSCLC tumor specimens. (A) H358 cells (non-silenced, mock-transfected and shRNA-PKM2) were implanted subcutaneously in nude
mice and the tumor growth of each mouse was monitored. The mice were euthanized on day 80 and the s.c. tumors were surgically excised. The tumor specimens were
fixed with 4% paraformaldehyde, embedded in OCT, cryo-sectioned, and immunostained with anti-PKM2 antibody. PKM2 was stained with Alexa 594 (red) and
DAPI was used for nuclear staining (blue). The sections were viewed in Nikon fluorescence microscope at 200 x magnification. (B) Extent of PKM2 immunostaining
in cytoplasm and nucleus was evaluated as�1+ negative; 2+ positive; 3+ strongly positive. % positive of total number of tumor cells was shown as mean ± SD.
https://doi.org/10.1371/journal.pone.0217131.g007
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significantly affected cell viability in all NSCLC cell lines and impaired the ability to form colo-
nies in vitro, suggesting that PKM2 enzyme activity is important for tumor growth in NSCLC
cells. The normal lung fibroblast cell lines failed to show such changes after targeting PKM2.
Previously published results have shown that PKM2 can interact with mutant EGFR and
HSP90 and prolonged the protein half-life of EGFR in lung cancer cells [14]. It is also reported
that PKM2 supports tumor growth through regulating the expression of gene that involved in
cell proliferation, migration and apoptosis [26]. Our present data have demonstrated a unique
role of PKM2 as its enzyme inhibition by either SMI or gene silencing can influence the tumor
growth in vitro and in vivo.
Elevated PKM2 is also associated with disease aggressiveness and poor overall survival of
patients with signet ring cell gastric cancer [34], gall bladder cancer [35, 36], and pancreatic
cancer [37]. Several published reports have shown that the deregulation of glucose metabolism
and overexpression of PKM2 are key regulators of aerobic glycolysis, also known as the War-
burg effect in situ in the tumor microenvironment [6, 38, 39]. This may be a consequence of
the primary function of PKM2, which is to catalyze the phosphorylation from phosphoenol
pyruvate to pyruvate at the last step of glycolysis, leading to generation of ATP needed for
tumor growth [40, 41]. Cortes-Cros et al., demonstrated that knocking down of PKM2 in
colon carcinoma cell lines led to a decrease in PKM2 activity and an increase in the pyruvate
kinase substrate phosphoenol pyruvate, leading to an increased macromolecular biosynthesis
required for rapid proliferation; suggesting that PKM2 influences the metabolic state of the
cells and has a role in tumor maintenance and growth in vivo [42, 43]. In a recent study of nod-
ular hypoplasia formation in Upk2-HRAS transgenic mice, overexpression of PKM2 was iden-
tified as the principal tyrosine-phosphorylated protein in the genesis of urothelial carcinomas
[44]. PKM2 is also involved in cancer initiation and progression [19, 29].
Our data demonstrated that targeting PKM2 with SMI and shRNA-PKM2 affected cell via-
bility and clonogenicity of NSCLC cells in vitro, which confirmed our results that PKM2 is a
growth supportive factor We further investigated the mechanism for decreased cell viability
and clonogenicity in PKM2 targeted NSCLC cells. We observed that SMI and shRNA-PKM2
both downregulated PKM2 mRNA and decreased PKM2 activities, which correlated inversely
with the number of apoptotic nuclei in targeted tumor cell populations. These changes are also
associated with increased Caspase 3/7 activities in NSCLC cells upon treating them with SMI
or shRNA-PKM2, which is a hallmark of apoptosis suggesting that SMI or shRNA-PKM2
affected the cell viability by inducing Caspase 3/7 mediated apoptosis. Similar observations
have been made by Goldberg and Sharp, who showed that targeting PKM2 with encapsulated
siRNAs resulted in decreased cell viability and increased apoptosis in 10 members of the NCI-
60 panel representing multiple types of cancer cell lines while having little effect in normal
fibroblasts or endothelial cells and tumor regression in vivo mouse model [20]. It was also
shown that shRNA-PKM2 induced apoptosis in vitro and in vivo human lung cancer xeno-
grafts treated with docetaxel, which suggested that PKM2 could, to some extent, reverse che-
motherapy resistance to cancer therapy [45, 46].
Interestingly, we identified a distinct subcellular compartmentalization of PKM2 enzyme
activity and protein expression in cytoplasm and nucleus after targeting PKM2 by SMI or
shRNA-PKM2 in vitro. We observed that PKM2 targeting by both strategies had decreased
cytoplasmic and increased nuclear PKM2 enzyme activity in patient-derived established
NSCLC cell lines, which also corroborated with PKM2 expression examined by ICC assay in
vitro. Importantly, our in vivo mouse results also demonstrated such compartmentalization,
which could differentiate animals responding to the PKM2 targeted therapy. Interestingly, the
regressing xenografts had lower PKM2 in cytoplasm and nucleus while non-regressing tumor
specimens showed a significant and dramatic increase in nuclear PKM2.
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Despite its anti-proliferative activities in vitro, PKM2 inhibitor did not mediate significant
effects on in vivo tumor growth in two NSCLC tumor xenografts and did not show statistically
significant improvement of survival compared to control mice. The reason for lack of SMI
activity in vivo is not clear. It is possible that PMK2 inhibitor levels, being a small molecular
weight compound of 231.25 Da, were not retained in the tumor bed at a high enough level to
exert a measurable anti-tumor effect. In contrast, PKM2 was silenced robustly by shRNA in
tumor cells before xenograft development, which showed significant anti-tumor effects com-
pared to non-silenced and mock-transfected xenografts. Because gene silenced and mock-
transfected xenograft bearing mice were sacrificed on day 120 per our Institutional Animal
Care and Use Committee (ACUC) protocols, the survival curves were found non-significantly
separated in mock-transfected and PKM2 silenced group mice were not significant. The per-
cent survival in mock-transfected and non-silenced mice was also non-significant as non-
silenced group mice received transfection reagent without any DNA as additional control
compared to negative control DNA in mock-transfected group mice. Similar studies of silenc-
ing PKM2 in colorectal cancer cell lines modulated PKM2 to the nucleus in response to oxali-
platin treatment sensitivity and characterized chemoresistance [17]. It was also observed that
intrinsic resistance to gefitinib, an EGFR-tyrosine kinase inhibitor, is positively correlated with
nuclear PKM2 levels in colorectal cancer cells [18].
The significance of variable PKM2 subcellular distribution is not known. Our results show
that when PKM2 is downregulated by SMI or gene silencing, subcellular compartmentaliza-
tion of PKM2 occurs. It is also not known that other types of PKM2 inhibitors critically play a
similar role in subcellular compartmentalization of PKM2 in NSCLC in vitro or in vivo models
of different types of human cancers. It is likely that PKM2 can have limited role as a biomarker
of therapeutic response in certain types of cancer with different pathological grade and clinical
stage (TNM). Additional studies in larger sample size of cancer subjects with different patho-
logical grade and clinical stage (TNM) can potentially establish its meaningful role as a bio-
marker of therapeutic response in clinical settings. Why PKM2 is compartmentalized is not
clear. PKM2 has been reported to be localized in the cell nucleus as a dimer that functions as
an active protein kinase; whereas, PKM2 in its tetrameric form is localized in the cytosol and is
an active pyruvate kinase [15]. It is possible that PKM2 functions as a protein kinase when is
downmodulated by SMI. Additional studies are needed to unravel the significance of this
compartmentalization. However, subcellular compartmentalization of PKM2 may have a role
as a biomarker of response in distinguishing groups with therapeutic response versus no
response when they were administered with anti-PKM2 therapy.
Supporting information
S1 Fig. Extent of immunostaining intensity for PKM2 expression in NSCLC cell lines.
Immunocytochemical assay was performed to evaluate the intensity of PKM2 immunostaining
in NSCLC cells using rabbit monoclonal anti-PKM2 antibody and alexa 595 conjugated goat
anti rabbit IgG antibody. The immunostained cells were viewed at 200X magnification.
(TIF)
S1 Table. Immunocytochemical (ICC) analysis for PKM2 in NSCLC cell lines. Extent of
ICC was evaluated as� 1+, weakly positive; 2+, strongly positive; 3+ stronger;4+, strongest.
Percent positive field was counted after viewing PKM2positive cells at 200X magnification and
shown in the parenthesis.
(DOC)
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S2 Table. ICC analysis of PKM2 in PKM2 targeted NSCLC cell lines. Extent of ICC was
evaluated as� 1+, weakly positive; 2+, strongly positive; 3+ stronger;4+, strongest. Percent
positive field was counted after viewing PKM2positive cells at 200X magnification and shown
in the parenthesis.
(DOCX)
S3 Table. Analysis of subcellular compartmentalization of PKM2 in PKM2 targeted
NSCLC cell lines. Extent of ICC was evaluated as� 1+, weakly positive; 2+, strongly positive;
3+ stronger;4+, strongest. Percent positive field was counted after viewing PKM2positive cells
at 200X magnification and shown in the parenthesis.
(DOC)
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